Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients
- 15 July 1980
- Vol. 46 (2) , 256-260
- https://doi.org/10.1002/1097-0142(19800715)46:2<256::aid-cncr2820460206>3.0.co;2-q
Abstract
Two hundred ten patients with advanced adenocarcinoma of the lung were entered into a two‐arm randomized trail. Cytoxan + CCNU + methotrexate was compared to Adriamycin and procarbazine. The tumor response to CCM was significantly higher than the tumor response to Adriamycin and procarbazine. No significant difference existed between the two treatments with respect to survival. Initial performance status, weight loss prior to therapy, and response to therapy were all found to be significant prognostic factors. Median survival time relative to responders in both treatment groups was 31.7 weeks and 15.8 weeks for non‐responders.This publication has 10 references indexed in Scilit:
- The changing histopathology of lung cancer.A review of 1682 casesCancer, 1977
- PLATINUM-BASED POLYCHEMOTHERAPY VERSUS DIANHYDROGALACTITOL IN ADVANCED NON-SMALL CELL LUNG-CANCER1977
- Surgical therapy of lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 1976
- Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patientsCancer, 1976
- CYCLOPHOSPHAMIDE, ADRIAMYCIN, METHOTREXATE, AND PROCARBAZINE (CAMP)-EFFECTIVE 4-DRUG COMBINATION CHEMOTHERAPY FOR METASTATIC NON-OAT CELL BRONCHOGENIC CARCINOMA1976
- ADRIAMYCIN IN TREATMENT OF FAR-ADVANCED LUNG-CANCER1976
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinomaCancer, 1948